SG&A Efficiency Analysis: Comparing Novartis AG and Evotec SE

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Novartis AG and Evotec SE have showcased contrasting trends in their SG&A expenditures.

Novartis AG: A Steady Giant

From 2014 to 2023, Novartis AG maintained a robust SG&A expenditure, averaging around $14.5 billion annually. Despite a slight decline in 2023, their consistent investment underscores their commitment to maintaining a strong market presence.

Evotec SE: A Rising Star

Conversely, Evotec SE's SG&A expenses surged by over 840% from 2014 to 2023, reflecting their aggressive growth strategy. This increase highlights their expanding operations and market reach.

Conclusion

While Novartis remains a steady giant, Evotec's rapid growth trajectory is a testament to their dynamic approach in the pharmaceutical sector.